Syndrome de l’intestin irritable : rôle de la flore et intérêt potentiel des probiotiques

Irritable bowel syndrome: role of intestinal flora and potential role of probiotics

Résumé

La mise en évidence d’un état pro-inflammatoire au cours du SII a permis d’émettre l’hypothèse qu’il pouvait exister des altérations de la flore digestive au cours du SII. Par rapport aux sujets sains, quelques travaux très récents suggèrent qu’il existe un déséquilibre qualitatif de la flore colique chez ces patients. Par ailleurs, d’autres travaux, émanant principalement d’une seule équipe, suggèrent qu’il existe des anomalies quantitatives de la flore, ce qui pourrait être une cible thérapeutique. Les probiotiques, en modulant l’équilibre de la flore digestive, sont une piste thérapeutique intéressante. Quelques études ont montré que certains probiotiques étaient susceptibles d’améliorer de façon prolongée les patients atteints de SII.

Abstract

The demonstration of a pro-inflammatory condition as part of IBS has resulted in the suggestion that there may be intestinal flora alterations with irritable bowel syndrome. With respect to healthy subjects, some very recent research has suggested that a qualitative imbalance of intestinal flora exists in these patients. Moreover, further research from another group found quantitative differences of flora which could be a therapeutic target. Probiotics, by modulating intestinal flora balance, are an interesting therapeutic option. A few studies have demonstrated that some probiotics could have long-lasting improvements for patients suffering from irritable bowel syndrome.

This is a preview of subscription content, access via your institution.

Références

  1. 1.

    Longstreth GF, Thompson WG, Chey WD, et al. (2006) Functional bowel disorders. Gastroenterology 130: 1480–1491

    PubMed  Article  Google Scholar 

  2. 2.

    Barbara G, Stanghellini V, Brandi G, et al. (2005) Interactions between commensal bacteria and gut sensorimotor function in health and disease. Am J Gastroenterol 100: 2560–2568

    PubMed  Article  CAS  Google Scholar 

  3. 3.

    Di Stefano M, Fiore JR, Pepe V, et al. (2006) Role of colonic fermentation in the perception of colonic distention in irritable bowel syndrome and functional bloating. Clin Gastroenterol Hepatol 4: 1242–1247

    PubMed  Article  Google Scholar 

  4. 4.

    Balsari A, Ceccarelli A, Dubini F, et al. (1982) The fecal microbial population in the irritable bowel syndrome. Microbiologica 5: 185–194

    PubMed  CAS  Google Scholar 

  5. 5.

    Swidsiski A, Khilkin M, Ortner M (1999) Alteration of bacterial concentration in colonic biopsies from patients with irritable bowel syndrome. Gastroenterology 116: A1

    Article  Google Scholar 

  6. 6.

    Kassinen A, Krogus-Kurikka L, Makivuokko H, et al. (2007) The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology 133: 24–33

    PubMed  Article  CAS  Google Scholar 

  7. 7.

    King TS, Elia M, Hunter JO (1998) Abnormal colonic fermentation in irritable bowel syndrome. Lancet 352: 1187–1189

    PubMed  Article  CAS  Google Scholar 

  8. 8.

    Lin HC (2004) Small intestinal bacterial overgrowth. A framework for understanding irritable bowel syndrome. JAMA 292: 852–858

    PubMed  Article  CAS  Google Scholar 

  9. 9.

    Pimentel M, Chatterjee S, Chow EJ, et al. (2006) Neomycin improves constipation-predominant irritable bowel syndrome in a fashion that is dependent on the presence of methane gas: sub-analysis of a double-blind randomized controlled study. Dig Dis Sci 51: 1297–1301

    PubMed  Article  CAS  Google Scholar 

  10. 10.

    Pimentel M, Chow EJ, Lin HC (2003) Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. A double-blind, randomized, placebo-controlled study. Am J Gastroenterol 98: 412–419

    PubMed  Google Scholar 

  11. 11.

    Hasler WL (2003) Lactulose breath testing, bacterial overgrowth, and IBS: just a lot of hot air? Gastroenterology 125: 1898–1900

    PubMed  Article  Google Scholar 

  12. 12.

    Posserud I, Statzer PO, Bjornsson ES, et al. (2007) Small intestinal bacterial overgrowth in patients with irritable bowel syndrome. Gut 56: 802–808

    PubMed  Article  Google Scholar 

  13. 13.

    Lupascu A, Gabrielli M, Lauritano EC, et al. (2005) Hydrogen glucose breath test to detect small intestinal bacterial overgrowth: a prevalence case-control study in irritable bowel syndrome. Aliment Pharmacol Ther 22: 1157–1160

    PubMed  Article  CAS  Google Scholar 

  14. 14.

    Dear KL, Elia M (2005) Do interventions which reduce colonic bacterial fermentation improve symptoms of irritable bowel syndrome? Dig Dis Sci 50: 758–766

    PubMed  Article  CAS  Google Scholar 

  15. 15.

    Pimentel M, Park S, Mirocha J, et al. (2006) The effect of a nonabsorbed antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome. A randomized trial. Ann Intern Med 145: 557–563

    PubMed  Google Scholar 

  16. 16.

    Sharara AI, Aoun E, Abdul-Baki H, et al. (2006) A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence. Am J Gastroenterol 101: 326–333

    PubMed  Article  CAS  Google Scholar 

  17. 17.

    Quigley EMM, Flourie B (2007) Probiotics and irritable bowel syndrome: a rationale for their use and an assessment of the evidence to date. Neurogastroenterol Motil 19: 166–172

    PubMed  Article  CAS  Google Scholar 

  18. 18.

    Nobaek S, Johansson ML, Molin G, et al. (2000) Alterations of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am J Gastroenterol 95: 1231–1238

    PubMed  Article  CAS  Google Scholar 

  19. 19.

    O’sullivan MA, O’Morain CA (2000) Bacterial supplementation in the irritable bowel syndrome. A randomised double-blind placebo-controlled crossover study. Dig Liver Dis 32: 302–304

    Article  Google Scholar 

  20. 20.

    Niedzelin K, Kordecki H, Birkenfeld B (2001) A controlled, double blind, randomized study on the efficacy of Lactobacilus plantarum 299 V in patients with irritable bowel syndrome. Eur J Gastroenterol 13: 1143–1147

    Article  Google Scholar 

  21. 21.

    Sen S, Mulan MM, Parker TJ, et al. (2002) Effect of Lactobacillus plantarum 229 V on colonic fermentation and symptoms of irritable bowel syndrome. Dig Dis Sci 47: 2615–2620

    PubMed  Article  CAS  Google Scholar 

  22. 22.

    Kim HJ, Camilleri M, McKinzie S, et al. (2003) A randomized controlled trial of a probiotic, VSL# 3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 17: 895–904

    PubMed  Article  CAS  Google Scholar 

  23. 23.

    Kim HJ, Vazquez Roque MI, Camilleri M, et al. (2005) A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating. Neurogastroenterol Motil 17: 687–696

    PubMed  Article  CAS  Google Scholar 

  24. 24.

    Kajander K, Hattaka K, Poussa T, et al. (2005) A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: a controlled 6-month intervention. Aliment Pharmacol Ther 22: 387–394

    PubMed  Article  CAS  Google Scholar 

  25. 25.

    Niv E, Naftali T, Hallack R, et al. (2005) The efficacy of Lactobacillus reuteri ATCC 55730 in the treatment of patients with irritable bowel syndrome — a double blind, placebo-controlled, randomized study. Clin Nutr 24: 925–931

    PubMed  Article  Google Scholar 

  26. 26.

    O’Mahony L, McCarthy J, Kelly P, et al. (2005) Lactobacillus and Bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 128: 541–551

    PubMed  Article  Google Scholar 

  27. 27.

    Whorwell PJ, Altringer L, Morel J, et al. (2006) Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol 101: 1581–1590

    PubMed  Article  Google Scholar 

  28. 28.

    Guyonnet D, Chassany O, Ducrotté P, et al. (2007) Effect of a fermented milk containng Bifidobacterium animalis DN-173010 on health-related quality of life and symptoms in primary care adult irritable bowel syndrome. A multicenter, randomised, double-blind controlled trial. Aliment Pharmacol Ther 26: 475–486

    PubMed  CAS  Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to P. Ducrotté.

About this article

Cite this article

Ducrotté, P. Syndrome de l’intestin irritable : rôle de la flore et intérêt potentiel des probiotiques. Colon Rectum 1, 237–241 (2007). https://doi.org/10.1007/s11725-007-0062-8

Download citation

Mots clés

  • Syndrome de l’intestin irritable
  • Probiotiques
  • Flore bactérienne
  • Colonisation bactérienne chronique

Keywords

  • Irritable bowel syndrome
  • Probiotics
  • Intestinal flora
  • Chronic bacterial colonization